GlaxoSmithKline is seeking binding bids by next month for a portfolio of mature drugs worth more than $3 billion, marketed in North America and western Europe.
Brands for sale include antidepressant Paxil, migraine treatment Imitrex, Zantac for stomach acid and Zofran for nausea. GSK intends to retain the rights to these products in emerging markets, where sales continue to grow.
The drugmaker is open to selling the products as a single unit or splitting them up by region.
Potential bidders include private equity investors KKR, Denmark's Lundbeck and India's Lupin.
Read the Reuter's press release